12:00 AM
 | 
May 25, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Genasense injection oblimersen sodium: Phase III ongoing

Genta said an independent data monitoring board recommended continuation of the double-blind, placebo-controlled, international Phase III AGENDA trial based on planned analyses for safety and futility based on PFS. The study is evaluating...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >